Sign In
18 Aug 2014 07:00
Belixos® now available through Amazon in Germany and UK
Leverkusen, 18 August 2014 - Biofrontera (AIM/FSE:B8F), the European biopharmaceutical company, announces that its derma-cosmetics products Belixos® Crème and Belixos® Liquid are now available on Amazon.de and Amazon.uk.
Both Belixos® products contain valuable ingredients extracted in a complex and very gentle process from Mahonia aquifolium, a medicinal plant that has been used for centuries by North American Indians. In the crème this is supplemented by the antibacterial properties of green tea and the soothing effects of chamomile to create a unique active ingredient combination. Moisturizing oat, urea and the zinc-PCA complex against dandruff complement the Mahonia extract in Belixos® Liquid. With their innovative biocolloid formulations Belixos® products provide a balanced combination of active substances.
The sound scientific basis behind Belixos® and the unique combination of valuable plant ingredients are intended to set new standards in the highly competitive active cosmetics market. In people suffering from itchiness or chronic ailments, such as atopic dermatitis or psoriasis, the combination of caring and regenerative effects may reduce the need for medical treatment.
The Belixos® product range is gradually being expanded. The first of the new products, the scalp tonic Belixos® Liquid, was launched at the beginning of 2014, Belixos® Gel and Belixos® Protect are to follow in the course of the year. The gel is intended as regenerative daily care for skin with acne and rosacea, Belixos® Protect is a day cream for photodamaged skin with protective anti-aging properties.
Prof. Hermann Lübbert, Chief Executive Officer of Biofrontera commented: "The UK is the first country outside Germany in which we have made our Belixos® products available. Amazon provides a perfect platform to offer these products to a wide group of people seeking care for itching or inflamed skin. We advise everybody who experiences itching after a mosquito bite or due to eczema, or who has a sunburn, to give Belixos® Crème a chance."
Enquiries
Biofrontera AG Prof. Hermann Lübbert, Chief Executive Officer Thomas Schaffer , Chief Financial Officer Anke zur Mühlen, Corporate Communications | +49 (0) 214 87 63 2 0 press@biofrontera.com www.biofrontera.com
|
Brainwell Asset Solutions Jürgen Benker | +49 (0) 152 08931514 |
finnCap (Nomad and Broker) Geoff Nash / Christopher Raggett (Corporate Finance) Steven Norcross(Corporate Broking) | +44(0) 20 7220 0500 |
Seton Services Limited (IR) Toni Vallen | +44 (0) 20 7603 6797 |
Gable Communications John Bick | +44 (0) 20 7193 7463 +44 (0) 7872 061007 |
Notes to Editors:
Biofrontera AG (AIM/FSE: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development and distribution of dermatological drugs and medical cosmetics for the treatment and care of skin diseases. Biofrontera's main product is Ameluz®, a prescription drug approved for use in Europe for the treatment of mild to moderate Actinic Keratosis (superficial skin cancer) by photodynamic therapy (light therapy). Biofrontera is the first small German pharmaceutical company to receive a centralized approval for a drug developed in-house. The Company is looking to further develop Ameluz® for use in Basal Cell Carcinoma and is currently progressing through regulatory approvals to sell the product in other territories, in particular the largest pharmaceutical market, the USA.
In addition, the Company markets the Belixos® cosmetic series with plant extracts, currently available in cream and liquid formulations which offer nurturing and regenerating effects for people suffering from pruritus, dry skin or chronic ailments such as eczema or psoriasis.
Biofrontera group was founded in 1997 by Prof. Dr. Hermann Lübbert, the CEO, and is headquartered in Leverkusen, Germany.
www.biofrontera.com
This press release contains forward-looking statements based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the assumptions expressed or implied in this press release to be faulty. Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on the forward-looking statements. Biofrontera AG disclaims any obligation to update these forward-looking statements to reflect future events or developments.
Follow the stocks
